Rashmi Kanagal-Shamanna, MD, of the MD Anderson Cancer Center, discusses the optical genome mapping platform and the clinical implications the technology will have for patients with acute myeloid leukemia and myelodysplastic syndromes.
Rashmi Kanagal-Shamanna, MD, Discusses Optical Genome Mapping
By Leah Sherwood, Rashmi Kanagal-Shamanna, MD - Last Updated: February 27, 2023Related Posts
A UC researcher secures $500K+ in grants to explore RAS inhibitors as potential treatments for acute myeloid leukemia.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
Naval Daver, MD reviews new targeted therapies transforming AML treatment in both young and older patient groups.
The name change will take effect on August 28, ahead of Blood Cancer Awareness Month in September.
A post-hoc analysis of long-term results in the AGILE trial adds to promising initial efficacy and safety results.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.